Years af­ter a ma­jor tri­al set­back, No­var­tis switch­es gears with SMA drug. This time they're try­ing it for Hunt­ing­ton's

Four years af­ter a Phase I/II set­back in spinal mus­cu­lar at­ro­phy (SMA), No­var­tis is hop­ing its drug branaplam will find more suc­cess in a new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.